You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in Estonia

Feb 2011

Price: $2,400

About this Report

About this Report

Delivery method: instant download
Report format: PDF doc_pdf.png (download a sample)
Market statistics: Excel workbook doc_excel_table.png (download a sample)

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in Estonia with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in Estonia, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in Estonia for free:

The Consumer Health in Estonia market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in Estonia?
  • What are the major brands in Estonia?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Sample Analysis

EXECUTIVE SUMMARY

Recession halts the growth in consumer health

The recession that continued also into 2010, although in less severe terms, continues to have a negative impact on consumer health in Estonia. The decline in consumers’ economic power has led them to adapt saving habits that have been also applied when it comes to purchasing pharmaceuticals. Although consumer health has survived significant negative growth, the sales declined slightly throughout the year and significant improvement is not expected. Although some positive growth was witnessed at the beginning of the year, this was attributed mainly to continuous discounting and the spread of seasonal illnesses such as flu during the colder winter months. Many leading medicine producers have also commented on the growth rates being a result of new product launches and discounting rather than the actual return of long-lasting growth in consumer health.

Distrust in generic medicines

The consumers in Estonia seem to be sceptical when it comes to generic pharmaceuticals that have the same active ingredients as the originals but are sold for a lower price than the original medicine. There has been a lot of discussion about whether the state should encourage people to buy cheaper medicines. In September 2010, the country initiated a campaign to increase the awareness of the people about the efficiency of generic medicines, as many seem to believe that these drugs are of lower quality due to their cheaper prices. The campaign’s objective is to help people spend money on medicine in a rational manner. Pharmacists are required to offer the range of products with the same ingredients and encourage them to choose the most affordable one, ensuring that they are aware of the equal effectiveness of all the products.

Competition favours strong players

As the heated competition continued into 2010, the strongest producers were able to dominate as they had more capital to provide sufficient advertising to keep their products visible. This became even more evident as the laws regarding medicine advertising were reviewed and the possibilities to advertise pharmaceuticals were extended. As people were trying to buy less medicine, discounting also became crucial in order for the products to maintain positive sales growth. Another advantage for the stronger manufacturers in addition to the previously mentioned ones was the ability to continue new product development as many producers commented on this as the main reason for the marginal positive growth at the beginning of 2010.

Chemists/pharmacies maintain leading position

Chemists/pharmacies continued as the dominating sales channel of the consumer health industry in Estonia. This was the only channel that was allowed to sell products considered as OTC medicines by the State Agency of Medicines. The public debate over whether some sales of these products should be allowed through other channels like grocery stores continues. A research study conducted by Statistics Estonia at the end of 2009 revealed that only 3% of pharmacies remain certain that they could survive in case this development takes place. The biggest effect would be on pharmacies positioned in rural areas.

Forecast period brings stagnation

Due to the hardships brought on by the recession and the general maturity of consumer health, no dynamic growth is expected during the forecast period. The growth rates are also expected to vary as categories such as child-specific OTC products still hold some room for growth. The development of the health and wellness trend also predicts some growth for consumer health provided the purchasing power of consumers regains its precrisis levels.

Table of Contents

Table of Contents

Consumer Health in Estonia - Industry Overview

EXECUTIVE SUMMARY

Recession halts the growth in consumer health

Distrust in generic medicines

Competition favours strong players

Chemists/pharmacies maintain leading position

Forecast period brings stagnation

KEY TRENDS AND DEVELOPMENTS

Changes in advertising of OTC medicines

The ageing population of Estonia

The emergence of private label in consumer health

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2005-2010
  • Table 2 Life Expectancy at Birth 2005-2010

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2005-2010
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2005-2010
  • Table 5 Consumer Health Company Shares 2006-2010
  • Table 6 Consumer Health Brand Shares 2007-2010
  • Table 7 Sales of Consumer Health by Distribution Format: % Analysis 2005-2010
  • Table 8 Sales of Consumer Health by Category and Distribution Format: % Analysis 2010
  • Table 9 Forecast Sales of Consumer Health by Category: Value 2010-2015
  • Table 10 Forecast Sales of Consumer Health by Category: % Value Growth 2010-2015

APPENDIX

OTC Registration and Classification

Advertising

Packaging and labelling

Distribution

Vitamins and dietary supplements registration and classification

Advertising of vitamins and dietary supplements

Retail distribution of vitamins and dietary supplements

Self-medication/self-care and preventative medicine

Switches

  • Summary 1 OTC Healthcare Switches 2008-2010

DEFINITIONS

  • Summary 2 Research Sources

Consumer Health in Estonia - Company Profiles

Magnum Medical AS - Consumer Health - Estonia

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

Massuno OÜ - Consumer Health - Estonia

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 7 Massuno OÜ: Competitive Position 2010

Tallinna Farmaatsiatehase AS - Consumer Health - Estonia

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 10 Tallinna Farmaatsiatehase AS: Competitive Position 2010

Walmark spol sro - Consumer Health - Estonia

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 13 Walmark spol sro: Competitive Position 2010

Adult Mouth Care in Estonia - Category Analysis

HEADLINES

TRENDS

  • Adult mouth care declined by nearly 3% in 2010 as value sales recorded EEK3 million in 2010. As in most consumer health categories, the main factor affecting adult mouth care products sales was the credit crunch in Estonia. Consumers were affected by the recession and adapted saving habits that brought down value sales. Adult mouth care products were not considered to be of primary necessity and therefore these products were bought on rare occasions. In addition, consumers downtraded towards purchasing cheaper products where available.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline Plcwas in the lead of adult mouth care in Estonia with nearly 19% value share. The company was successful due to its affordable brand Corsodyl Mint.The leader was followed by Walmark Sro. The latter company was strong on the market with its toothpaste brand Santoin which was used to prevent periodontosis. Although neither of the companies used significant advertising to promote these products, they maintained success due to the good positioning of their products in chemists/pharmacies. The overall market for adult mouth care in Estonia was rather segmented, without any manufacturer being able to dominate with a substantial corporate share.

PROSPECTS

  • Adult mouth care in Estonia is expected to grow by 2% in CAGR terms as value sales will reach EEK3 million by 2015. Adult mouth care products are expected to have recorded the last negative growth in 2010, and positive growth rates are expected from there on. The growth can be attributed to the improving situation in economic terms as people are expected to regain their precrisis purchasing power. This will enable them to gradually let go of their adapted saving habits and start spending on products that were not considered of primary necessity during the recession.

CATEGORY DATA

  • Table 11 Sales of Adult Mouth Care: Value 2005-2010
  • Table 12 Sales of Adult Mouth Care: % Value Growth 2005-2010
  • Table 13 Adult Mouth Care Company Shares 2006-2010
  • Table 14 Adult Mouth Care Brand Shares 2007-2010
  • Table 15 Forecast Sales of Adult Mouth Care: Value 2010-2015
  • Table 16 Forecast Sales of Adult Mouth Care: % Value Growth 2010-2015

Analgesics in Estonia - Category Analysis

HEADLINES

TRENDS

  • Analgesics sales declined by 4% as the category recorded value sales of EEK121 million in 2010. Estonians continued to use analgesics quite excessively also in 2010. This trend was the result of the hectic lifestyles and the general concept of analgesics as miracle drugs to relieve many symptoms. However, this widespread use did not mirror to value sales as at the same time consumers were trading down towards cheaper products. The introduction of generic medicines as equals to originals in Estonia continued, as the Estonian Health Insurance Fund launched a campaign to increase the popularity of these medicines. Estonians also tend to use stronger OTC analgesics as the leading products on the market are products with a 400mg concentration.

SWITCHES

COMPETITIVE LANDSCAPE

  • Nycomed SEFA AS led in analgesics, with a 22% retail value share in 2010. The company was especially strong in systemic analgesics where it held a 31% share. Berlin-Chemie AG followed as it held the second position in analgesics with a 19% share of all analgesics sales. This company led with 56% retail value share of topical analgesics/anaesthetic in 2010. Both of these leading companies invested heavily in intense advertising on television and their products were present on the market throughout the review period. This has made them trusted and valued by the Estonian consumers. GlaxoSmithKline Plc followed these companies with an 11% retail value share. The domestic Grindeks AS was fifth in analgesics with its more affordable systemic analgesics produced in Estonia and a share of 9%.

PROSPECTS

  • Analgesics is expected to see a growth of 1% in CAGR terms as sales of 2015 will reach EEK128 million. Due to the signs of the economy’s revival, people are expected to introduce less saving in regards to analgesics. In many cases, people buy analgesics to attempt self-medication and recovery at home rather than going to the doctor. Nevertheless, stronger sales are not expected as analgesics in Estonia is rather mature and the sales are only forecast to reach their precrisis levels. In addition, it is probable that generic brands will become increasingly popular as people start to perceive these products as equally efficient as the originals. The sales of analgesics are also likely to become available through channels such as supermarkets.

CATEGORY DATA

  • Table 17 Sales of Analgesics by Category: Value 2005-2010
  • Table 18 Sales of Analgesics by Category: % Value Growth 2005-2010
  • Table 19 Analgesics Company Shares 2006-2010
  • Table 20 Analgesics Brand Shares 2007-2010
  • Table 21 Forecast Sales of Analgesics by Category: Value 2010-2015
  • Table 22 Forecast Sales of Analgesics by Category: % Value Growth 2010-2015

Calming and Sleeping in Estonia - Category Analysis

HEADLINES

TRENDS

  • Calming and sleeping products in Estonia declined by 1% as value sales accounted for EEK5 million in 2010. Despite the hectic and stressful lifestyles of the Estonians, the recession forced consumers to downtrade and cut back on purchasing calming and sleeping products significantly. As budgets declined, people did not have resources to spend on products not considered essential for everyday life. In addition, a downtrading trend became prevalent as people started preferring cheaper brands to save money. Also, OTC calming and sleeping products were used only when seeking help for anxiety or sleep problems, and consumers turned to professional help when dealing with more serious issues. OTC calming and sleeping products were mainly used by working people or the elderly who had to deal with either stress or sleeping issues.

SWITCHES

COMPETITIVE LANDSCAPE

  • Walmark spol sro remained in the leading position in calming and sleeping in 2010, with its relatively new Benosen N20 product launched in 2007. The company held a corporate retail value share of 27% in 2010 due to this brand, which achieved its position with the help of advertising and affordable pricing. The leader was followed by Dom Pharma OÜ, which represents the affordable valerian-based pills under the brand name Palderjaniekstrakti Dražee. Although the latter brand does not receive significant advertising, it remains popular due to its affordability.

PROSPECTS

  • Calming and sleeping products in Estonia is expected to see growth by 1% in CAGR terms as value sales are forecast to reach EEK6 million by 2015. The growth is expected mainly because the first signs of the revival of the economy have been noticed. This makes the forecast outlook more positive than in previous years as people are starting to regain their economic confidence. This allows them to start spending on products that were not considered of primary necessity during the recession. In addition, as the hectic lifestyles in Estonia are becoming more common, people are increasingly seeking help from OTC calming and sleeping products to relieve stress and issues caused by it. Also, these products are likely to become available through supermarkets, which makes the purchasing much more convenient.

CATEGORY DATA

  • Table 23 Sales of Calming and Sleeping: Value 2005-2010
  • Table 24 Sales of Calming and Sleeping: % Value Growth 2005-2010
  • Table 25 Calming and Sleeping Company Shares 2006-2010
  • Table 26 Calming and Sleeping Brand Shares 2007-2010
  • Table 27 Forecast Sales of Calming and Sleeping: Value 2010-2015
  • Table 28 Forecast Sales of Calming and Sleeping: % Value Growth 2010-2015

Cough, Cold and Allergy (Hay Fever) Remedies in Estonia - Category Analysis

HEADLINES

TRENDS

  • Cough, cold and allergy (hay fever) remedies stagnated as value sales reached EEK141 million in 2010. Value sales did not improve as people continued to apply the saving habits they had adapted by choosing more affordable products or not buying these remedies at all. In addition, the spread of cold-related illnesses in 2010 was slightly less evident than in the colder months of 2009. People were also choosing cheaper products when possible and taking advantage of any discounts available on the market. Nevertheless, severe decline was not seen as consumers often preferred to attempt self-medication before visiting the doctor, as the queues for a doctor’s appointment are quite long in Estonia.

SWITCHES

COMPETITIVE LANDSCAPE

  • McNeil Products Ltd leads cough, cold and allergy (hay fever) remedies with a 21% share in 2010. The company markets the brand Sudafed, which sold for the total value of EEK14 million in 2009 and was recorded as the number one OTC medicine in Estonia. GlaxoSmithKline follows with 15% value share with the Coldrex brand, which was a bestseller in combination remedies throughout the review period. The brand has been successfully expanding. Both of the manufacturers invest a great deal to ensure adequate advertising to maintain the positions of their products, and also engage strongly in new product development. The producers are leaders in the market due to the well-established and highly trusted brand images they have created.

PROSPECTS

  • Cough, cold and allergy (hay fever) remedies is expected to record a growth of 2% in CAGR terms as values sales reach EEK153 million in 2015. Growth is forecast as people have started to regain their precrisis purchasing power. The sales of cough, cold and allergy remedies are also likely to become available through channels such as supermarkets. Nevertheless, value sales are not expected to grow over the precrisis levels due to the maturity of the market.

CATEGORY DATA

  • Table 29 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 30 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 31 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares 2006-2010
  • Table 32 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares 2007-2010
  • Table 33 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2010-2015
  • Table 34 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2010-2015

Digestive Remedies in Estonia - Category Analysis

HEADLINES

TRENDS

  • Digestive remedies grows by 3% as value sales record EEK53 million in 2010. Although the credit crunch continued to affect the category as people attempted to save by downtrading or not purchasing medicines at all, the category survived decline due to the switch of No-Spa, which was now classified as an OTC medicine. The product belongs to the most successful OTC medicines in Estonia.

SWITCHES

COMPETITIVE LANDSCAPE

  • Berlin-Chemie AG continues as leader by holding 17% retail value share in 2010. The leading position can be attributed to the company’s successful brand Espumisan, which was amongst the best-selling OTC medicines in 2010. This medicine has become trusted and well known amongst the Estonian consumers. The company continued to advertise this brand actively in printed media and television, making sure it maintains its visibility amongst consumers.

PROSPECTS

  • Digestive remedies is expected to grow 1% in CAGR terms as value sales reach EEK56 million in 2015. Growth is expected as the recession is showing signs of withdrawal and people are regaining their precrisis economic confidence. This enables them to start feeling more secure to spend money in categories that were not considered to be of primary importance. In addition, the rapid growth of indigestion problems in Estonia is likely to fuel the value and volume sales. The sales are also likely to increase as digestive remedies is expected to become available via other channels such as supermarkets.

CATEGORY DATA

  • Table 35 Sales of Digestive Remedies by Category: Value 2005-2010
  • Table 36 Sales of Digestive Remedies by Category: % Value Growth 2005-2010
  • Table 37 Digestive Remedies Company Shares 2006-2010
  • Table 38 Digestive Remedies Brand Shares 2007-2010
  • Table 39 Forecast Sales of Digestive Remedies by Category: Value 2010-2015
  • Table 40 Forecast Sales of Digestive Remedies by Category: % Value Growth 2010-2015

Ear Care in Estonia - Category Analysis

HEADLINES

TRENDS

  • Ear care declined by 1% as value sales accounted for EEK450,000 in 2010. Ear care products were mainly not seen as primary necessities, and saving by not buying these pharmaceuticals became very common. In addition, downtrading to cheaper brands had a negative influence on value sales. The majority of the population in Estonia continues to use cotton sticks to clean their ears despite warnings from doctors. Ear care products are often neglected, as consumers do not take the risks involved with cotton sticks very seriously.

SWITCHES

COMPETITIVE LANDSCAPE

  • Naveh Pharma Ltd leads the category with a value share of 56% in 2010. As the domestic company Galenos AS stopped all production activities in 2009, Naveh Pharma has ensured the leading position in the market with two products available – Clean Ears Aerosol and Dry Ears Aerosol. Although companies producing ear care products do not engage in significant advertising activities, this company has managed to ensure the lead with good positioning of its products in chemists/pharmacies. The leader was followed by Sigmapharm GmbH, which held a value share of 38%.

PROSPECTS

  • Ear care is forecast to see a CAGR of nearly 1% over the forecast period as value sales reach EEK470,000 by 2015. Growth is expected as the recession is showing signs of withdrawal and people are regaining their precrisis economic confidence. This enables them to start feeling more secure to spend on items that are not considered of primary necessity, including ear care products. In addition, the habit of using cotton sticks to clean ears is expected to become increasingly condemnable. This will lead to the growth of popularity of ear care products available in chemists/pharmacies.

CATEGORY DATA

  • Table 41 Sales of Ear Care: Value 2005-2010
  • Table 42 Sales of Ear Care: % Value Growth 2005-2010
  • Table 43 Ear Care Company Shares 2006-2010
  • Table 44 Ear Care Brand Shares 2007-2010
  • Table 45 Forecast Sales of Ear Care: Value 2010-2015
  • Table 46 Forecast Sales of Ear Care: % Value Growth 2010-2015

Emergency Contraception in Estonia - Category Analysis

HEADLINES

TRENDS

  • Emergency contraception in Estonia stagnated as value sales record EEK7 million in 2010. However, the category survived the decline as the product is often considered a necessity. Women continued to purchase emergency contraception as unwanted pregnancy was a concept completely detached from the economic crisis. Women perceived these products to be essential to avoid pregnancy. Saving at the expense of this product was rather complicated and as only two brands are available in Estonia, downtrading did not take place. In addition, the change towards increasingly using the one-pill-only-treatment Escapelle 1.5mg, instead of the two-pill-treatment Postinor-2, continued at a rapid pace.

COMPETITIVE LANDSCAPE

  • Richter Gedeon continued as the only manufacturer on the market with two products available. One was Postinor-2, which contained two tablets; the other, Escapelle 1.5mg, contained only one tablet instead of two. Postinor-2 has been available since 2003 when emergency contraception became available in Estonia. It had been the trusted leading brand until 2010. However, from 2006 it lost share due to the launch of Escapelle 1.5mg. The latter is more convenient and contemporary, as only one tablet has to be taken instead of two. As a result, Escapelle 1.5mg increased its retail value share from 9% in 2008 to 61% in 2010 as women became increasingly aware of its existence.

PROSPECTS

  • Emergency contraception is expected to grow slowly at 1% level in CAGR terms as value sales account for EEK8 million in 2015. Greater increase is not expected as the category has reached maturity in Estonia. In addition, as new innovative contraceptives are being launched, the necessity to take emergency contraception pills is likely to happen on fewer occasions.

CATEGORY DATA

  • Table 47 Sales of Emergency Contraception: Value 2005-2010
  • Table 48 Sales of Emergency Contraception: % Value Growth 2005-2010
  • Table 49 Emergency Contraception Company Shares 2006-2010
  • Table 50 Emergency Contraception Brand Shares 2007-2010
  • Table 51 Forecast Sales of Emergency Contraception: Value 2010-2015
  • Table 52 Forecast Sales of Emergency Contraception: % Value Growth 2010-2015

Eye Care in Estonia - Category Analysis

HEADLINES

TRENDS

  • Eye care in 2010 recorded a marginal negative growth as products were sold for a value of EEK11 million. As the Estonian consumers were opting to save money, they downtraded towards cheaper products or chose not to purchase eye care products at all as these were not considered of primary necessity.

SWITCHES

COMPETITIVE LANDSCAPE

  • Nycomed SEFA AS led sales in eye care in Estonia during 2010 with a corporate value share of 72%. This was due to the popularity of its Sulfametizol antibiotic eye care brand. The product was well advertised and was the only available OTC antibiotic eye care product. This resulted in its high popularity amongst consumers. In addition, the company’s products have been generally well positioned in chemists/pharmacies, making the products visible on the shelves.

PROSPECTS

  • Eye care is forecast to grow slightly in CAGR terms as sales are expected to stay at EEK11 million in 2015. As the first signs of the economy’s revival have been noted, people are expected to regain their precrisis purchasing powers. This will lead to increased comfort in purchasing products that were not considered of primary necessity during the hard times. Nevertheless, greater growth is not expected as eye care in Estonia is rather mature. The CAGR of eye care will be one of the lowest in consumer health

CATEGORY DATA

  • Table 53 Sales of Eye Care by Category: Value 2005-2010
  • Table 54 Sales of Eye Care by Category: % Value Growth 2005-2010
  • Table 55 Standard Eye Care by Type: % Value Breakdown 2007-2010
  • Table 56 Eye Care Company Shares 2006-2010
  • Table 57 Eye Care Brand Shares 2007-2010
  • Table 58 Forecast Sales of Eye Care by Category: Value 2010-2015
  • Table 59 Forecast Sales of Eye Care by Category: % Value Growth 2010-2015

Herbal/Traditional Products in Estonia - Category Analysis

HEADLINES

TRENDS

  • Herbal/traditional products in Estonia decreased by 3% and value sales recorded EEK49 million in 2010. The recession in Estonia had a negative impact on value sales of herbal/traditional products as people were attempting to save. This had a direct effect on sales, as people were buying fewer herbal/traditional products and also continued to trade down towards cheaper products. The notion of many people preferring herbal/traditional products instead of standard medicines did not save the category from decline.

COMPETITIVE LANDSCAPE

  • Although the category remained very segmented, Dansk Droge A/S was in the lead with a corporate value share of 7%. Pharma Nord ApS followed closely with a share of 6% and Richard Bittner GmbH took the third spot with a share of 5%. All of these companies manage well-known brands and continue to put effort into keeping their products visible with the help of advertising and positioning.

PROSPECTS

  • Herbal/traditional products is forecast to grow by under 1% in CAGR terms over the forecast period as value sales reach EEK51 million in 2015. As the recession is slowly showing signs of withdrawal, people are expected to get back their precrisis purchasing power. This will enable them to start purchasing more herbal/traditional remedies. In addition, they will be also able to choose more expensive products. In addition, the perception of herbal/traditional remedies being more body-friendly in comparison to standard medicines is growing. This will help along the growth of the category.

CATEGORY DATA

  • Table 60 Sales of Herbal/Traditional Products: Value 2005-2010
  • Table 61 Sales of Herbal/Traditional Products: % Value Growth 2005-2010
  • Table 62 Herbal/Traditional Products Company Shares 2006-2010
  • Table 63 Herbal/Traditional Products Brand Shares 2007-2010
  • Table 64 Forecast Sales of Herbal/Traditional Products: Value 2010-2015
  • Table 65 Forecast Sales of Herbal/Traditional Products: % Value Growth 2010-2015

Medicated Skin Care in Estonia - Category Analysis

HEADLINES

TRENDS

  • Medicated skin care declined by 2% as value sales recorded EEK27 million in 2010. Serious issues, such as cuts in salaries or layoffs from employment in the worst-case scenario, have impacted the purchasing power of consumers in a negative way. The vast majority of the population have downtraded towards cheaper products or decided to stop purchasing medicines. In addition, medicated skin care available in pharmacies is often substituted with cheaper products that are available in supermarkets. These are purchased in the hope of having the same effect as skin care products from pharmacies. This trend is evident in the case of shampoos, where medicated shampoos are replaced with nonmedicated shampoos. For example, antifungal shampoos such as Nizoral receive tough competition from the nonmedicated brand Head & Shoulders available at a lower price.

SWITCHES

COMPETITIVE LANDSCAPE

  • The multinational GlaxoSmithKline continued to lead sales during 2010, with a value share of 32% as the company’s Nix and Zovirax brands were amongst the best-selling medicated skin care products in Estonia during the review period. In addition, they are amongst the most popular OTC products in Estonia. GlaxoSmithKline continued to invest in advertising to maintain the well-established and trusted brands. Beiersdorf AG ranked second with a corporate retail value share of 11% in 2010. The company’s well-known Eucerin brand is well positioned in chemists/pharmacies and the company also actively markets its products to the public. Since 2006, the company has operated an information and consultation stand in Tallinn. In 2007, an Estonian version of the Eucerin website was launched to bring the brand closer to its consumers.

PROSPECTS

  • Medicated skin care is forecast to see growth of nearly 2% as value sales reach EEK27 million by 2015. As the recession is showing signs of improvement, people are expected to gain back their precrisis purchasing powers. This will enable them to start spending more on medicated skin care, whereas during the credit crunch these products were often left unpurchased. In addition, herbal/traditional skin care is expected to grow more popular as the trend towards healthy lifestyles is taking over every consumer product category. Herbal/traditional medicated skin care is often seen as equally efficient as yet more body friendly than standard products.

CATEGORY DATA

  • Table 66 Sales of Medicated Skin Care by Category: Value 2005-2010
  • Table 67 Sales of Medicated Skin Care by Category: % Value Growth 2005-2010
  • Table 68 Medicated Skin Care Company Shares by Value 2006-2010
  • Table 69 Medicated Skin Care Brand Shares 2007-2010
  • Table 70 Hair Loss Treatments Brand Shares 2007-2010
  • Table 71 Forecast Sales of Medicated Skin Care by Category: Value 2010-2015
  • Table 72 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2010-2015

NRT Smoking Cessation Aids in Estonia - Category Analysis

HEADLINES

TRENDS

  • NRT smoking cessation aids saw decline of 8% as sales accounted for a value of EEK5 million in 2010. Although the number of smokers in Estonia is decreasing, NRT smoking cessation aids sales have not increased. As consumers in Estonia were trying to save, smoking habits were often abandoned without the help of NRT smoking cessation aids. In other cases, people were not quitting smoking at all as they considered these products to be too costly. When consumers indeed decided to use NRT smoking cessation aids, cheaper products such as NRT gum were often preferred over NRT patches.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline Plc continues to dominate NRT smoking cessation aids with a value share of 57% in 2010. The company has been a long-term leader in NRT smoking cessation aids in Estonia and continues to advertise its products to maintain its position. Its brand Niquitin has the advantages of premium positioning and well-established brand name.

PROSPECTS

  • No significant expansion for the market of NRT smoking cessation aids is seen as value is expected to reach EEK7 in 2015, although growing by 5% in CAGR terms. As the impact of the economic crisis is still evident, people are likely to continue saving at the expense of these products. Nevertheless, some growth is expected by the end of the forecast period as the economic stability and purchasing power of Estonians begin to grow. This will allow them to spend on products that were considered unnecessary during the recession. In addition, as people begin to feel more confident in spending more money, the trend towards healthy lifestyles will grow stronger, and smoking is likely to be seen as a lethal habit. With more and more people attempting to quit smoking, value sales of NRT smoking cessation aids are likely to turn to positive growth.

CATEGORY INDICATORS

  • Table 73 Number of Smokers by Gender 2005-2010

CATEGORY DATA

  • Table 74 Sales of NRT Smoking Cessation Aids by Category: Value 2005-2010
  • Table 75 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2005-2010
  • Table 76 NRT Gum Flavours: % Value Breakdown 2006-2010
  • Table 77 NRT Smoking Cessation Aids Company Shares 2006-2010
  • Table 78 NRT Smoking Cessation Aids Brand Shares 2007-2010
  • Table 79 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2010-2015
  • Table 80 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2010-2015

OTC Triptans in Estonia - Category Analysis

TRENDS

  • Triptans are only available as Rx medicines in Estonia. Triptans that are prescribed include Zolmitriptan Actavis 5mg (produced by Actavis Ltd), Imigran (produced by GlaxoSmithKline Ltd), Sumatriptan Sandoz (produced by Sandoz) and Cinie (produced by Zentiva).

Sports Nutrition in Estonia - Category Analysis

HEADLINES

TRENDS

  • Sports nutrition in Estonia declined by nearly 5% as value sales accounted for EEK720,000 in 2010. As many people ended their memberships at various sports clubs, the sales of sports nutrition in Estonia declined. People found these products to be of secondary importance, and saving at the expense of sports nutrition was not seen as a great sacrifice. The category remained important for specific consumers such as sportsmen.

COMPETITIVE LANDSCAPE

  • MuscleTech Research & Development Inc was in the lead with a corporate value share of 33% in 2010. All Stars Fitness Products GmbH followed with a share of 13% and Koelbel Trainingsforschung GmbH held the third place with a share of 10%. All of these companies marketed a wide range of products and offered various discounts. In addition, they made sure that their products obtained good positioning and stayed visible for the consumers. They also continued to develop their brands further by launching new products. All of these aspects have made their brands the best known and trusted amongst Estonian consumers.

PROSPECTS

  • Sports nutrition in Estonia expected to grow by 1% in CAGR terms as value sales are forecast to reach EEK5 million by 2015. This growth is expected as with the recovery of the economy people will start to feel more confident in economic terms. In addition, the growing health and wellness trend will act as a boost to the sales of sports nutrition. Nevertheless, greater growth is not expected as the category is reaching maturity. In addition, a large part of the products are targeted at a specific smaller consumer group who are professionally involved in fitness and bodybuilding.

CATEGORY DATA

  • Summary 14 Sports Nutrition, category rankings 2010
  • Table 81 Sales of Sports Nutrition: Value 2005-2010
  • Table 82 Sales of Sports Nutrition: % Value Growth 2005-2010
  • Table 83 Sports Nutrition By Format: % Value Breakdown 2007-2010
  • Table 84 Sports Nutrition Company Shares 2006-2010
  • Table 85 Sports Nutrition Brand Shares 2007-2010
  • Table 86 Forecast Sales of Sports Nutrition: Value 2010-2015
  • Table 87 Forecast Sales of Sports Nutrition: % Value Growth 2010-2015

Vitamins and Dietary Supplements in Estonia - Category Analysis

HEADLINES

TRENDS

  • Vitamins and dietary supplements declined by 3% in 2010 as value sales accounted for EEK149 million. Consumers attempted to save whilst purchasing fewer vitamins and dietary supplements. As the recession hit Estonia, consumers were forced to tighten their budgets and make cuts to purchases wherever possible. Due to vitamins and dietary supplements not being considered as primary necessities, people in Estonia started to purchase them in smaller volumes than ever before. This behaviour continued also into 2010, although in somewhat lesser measure as the economy was showing some signs of recovery. In addition, downtrading towards cheaper products continued as a wide selection of vitamins and dietary supplements products in Estonia were offered in many price ranges.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • Nycomed SEFA maintained the lead in this competitive category with a value share of 11% in 2010. The leader was followed by Walmark, which held 10% share. Vitabalans Oy trailed the leaders with its 8% share. All of the companies had a wide and successful product range available. In addition, they continued to invest in both advertising and new product launches.

PROSPECTS

  • Vitamins and dietary supplements is expected to grow by 1% CAGR as value sales are predicted to reach EEK156 million in 2015. As the recession is showing signs of withdrawal, consumers are likely to gain back their precrisis purchasing power. This will enable them to feel economically secure and start spending on vitamins and dietary supplements that were not considered to be primary necessities during the recession. This growth will also be fuelled by the growing health and wellness trend. Value sales are bound to increase also, because consumers in Estonia will start to purchase pricier products once again. Nevertheless, as consumers are increasingly developing views about most of the vitamins and supplements being inefficient, the value sales are not likely to exceed those in the precrisis times.

CATEGORY DATA

  • Summary 15 Dietary Supplements: Brand Ranking by Positioning 2010
  • Table 88 Sales of Vitamins and Dietary Supplements by Category: Value 2005-2010
  • Table 89 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2005-2010
  • Table 90 Dietary Supplements by Positioning 2006-2010
  • Table 91 Vitamins and Dietary Supplements Company Shares 2006-2010
  • Table 92 Vitamins and Dietary Supplements Brand Shares 2007-2010
  • Table 93 Vitamins Brand Shares 2007-2010
  • Table 94 Dietary Supplements Brand Shares 2007-2010
  • Table 95 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2010-2015
  • Table 96 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2010-2015

Weight Management in Estonia - Category Analysis

HEADLINES

TRENDS

  • Weight management products grew by 4% as sales recorded a value of EEK7 million in 2010. The category grew as the innovative obesity medicine Alli became available in Estonia in 2009. Alli received high volumes of advertising to ensure a successful entrance in the market. The high level of interest in this product shows that Estonians are conscious about their weight issues, especially as the rate of obesity is growing. In regards to general trends of weight management products in Estonia, they also produce seasonal increased sales in presummer periods and post-Christmas time.

COMPETITIVE LANDSCAPE

  • Glaxo Group Ltd took the lead of weight management in 2010 with 59% value share. The company successfully entered the market in 2009 as it introduced the highly anticipated obesity medicine Alli. Alli received a great deal of advertising to make it visible for the consumers. This worked as the Estonian consumers became instantly interested in the product, fuelling the high sales. Pierre Fabre and Erba Vita followed the leader with value shares of 8%. These companies market the brands of Elancyl and Cell Stop respectively.

PROSPECTS

  • Weight management is expected to grow by 3% in CAGR terms as value sales are predicted to reach EEK8 million in 2015. The growth will mainly be attributable to the continuing success of Alli, the only obesity product available in Estonia. In addition, as the recession is ending, people will be getting back their precrisis economic stability, enabling more people to try out this innovative product. The sales of weight management products in Estonia are also fuelled by the growing health and wellness trend, which is making people even more conscious about their weight.

CATEGORY DATA

  • Table 97 Sales of Weight Management by Category: Value 2005-2010
  • Table 98 Sales of Weight Management by Category: % Value Growth 2005-2010
  • Table 99 Weight Management Company Shares 2006-2010
  • Table 100 Weight Management Brand Shares 2007-2010
  • Table 101 Forecast Sales of Weight Management by Category: Value 2010-2015
  • Table 102 Forecast Sales of Weight Management by Category: % Value Growth 2010-2015

Wound Care in Estonia - Category Analysis

HEADLINES

TRENDS

  • Wound care in Estonia recorded value sales of EEK11 million, as the category declined by 1%. Wound care products suffered decline due to the economic crisis in Estonia as consumers became preoccupied with saving. They were adapting to new, lower budgets which did not allow for them to purchase healthcare products in the same amounts as before. In addition, consumers turned increasingly towards cheaper products on the market, dragging down the value sales of wound care products.

COMPETITIVE LANDSCAPE

  • Beiersdorf AG continued in the lead with a nearly 49% share. The success is mainly attributed to the well-known brand name Hansaplast, which offers a variety of products targeted at both children and adults. The brand is also heavily advertised to maintain its successful sales. Nevertheless, the company’s share declined somewhat from 2007 through 2010 as people started to use less known and cheaper brands as they had to adapt to the new economic conditions brought on by the credit crunch.

PROSPECTS

  • Wound care is forecast to see growth of 1% in CAGR terms as value sales are expected to reach EEK11 million in 2015. The slight growth is expected as the first signs of economic revival have been noted and people are starting to let go of their saving habits. This allows them to start spending more on wound care and also focusing more attention on premium brands. Nevertheless, greater growth is unlikely as wound care in Estonia is rather mature.

CATEGORY DATA

  • Table 103 Sales of Wound Care by Category: Value 2005-2010
  • Table 104 Sales of Wound Care by Category: % Value Growth 2005-2010
  • Table 105 Wound Care Company Shares 2006-2010
  • Table 106 Wound Care Brand Shares 2007-2010
  • Table 107 Forecast Sales of Wound Care by Category: Value 2010-2015
  • Table 108 Forecast Sales of Wound Care by Category: % Value Growth 2010-2015

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Child-Specific Analgesics
            • Child-Specific Acetaminophen
            • Child-Specific Aspirin
            • Child-Specific Combination Products - Analgesics
            • Child-Specific Diclofenac
            • Child-Specific Dipyrone
            • Child-Specific Ibuprofen
            • Child-Specific Ketoprofen
            • Child-Specific Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Child-Specific Cough, Cold and Allergy Remedies
          • Child-Specific Allergy Remedies
          • Child-Specific Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Child-Specific Digestive Remedies
          • Child-Specific Diarrhoeal Remedies
          • Child-Specific Indigestion and Heartburn Remedies
          • Child-Specific Laxatives
          • Child-Specific Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Acne Treatments
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Child-Specific Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
    • Vitamins and Dietary Supplements
      • Child-Specific Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
          • Non-Herbal Dietary Supplements
            • Calcium Supplements
            • Co-Enzyme Q10
            • Combination Non-Herbal Dietary Supplements
            • Eye Health Supplements
            • Fish Oils
              • Cod Liver Oil
              • Other Fish Oils
            • Glucosamine
            • Mineral Supplements
            • Omega-3-6-9 (Fish and Non-Fish)
            • Probiotic Supplements
            • Protein Powder
            • Royal Jelly
            • Sam-E
            • Other Non-Herbal Dietary Supplements
          • Tonics and Bottled Nutritive Drinks
          • Vitamins
            • Multivitamins
            • Single Vitamins
              • Vitamin A
              • Vitamin B
              • Vitamin C
              • Vitamin D
              • Vitamin E
              • Other Single Vitamins
        • Weight Management
          • Meal Replacement Slimming
          • OTC Obesity
          • Slimming Teas
          • Weight Loss Supplements
          • Other Slimming Products
        • Herbal/Traditional Products
          • Herbal/Traditional Analgesics
          • Herbal/Traditional Calming and Sleeping Products
          • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
          • Herbal/Traditional Digestive Remedies
          • Herbal/Traditional Medicated Skin Care
          • Herbal/Traditional Medicinal Teas
          • Herbal/Traditional Smoking Cessation Aids
          • Herbal/Traditional Child-Specific Dietary Supplements
          • Herbal/Traditional Dietary Supplements
          • Herbal/Traditional Tonics and Bottled Nutritive Drinks
        • Allergy Care
          • Allergy Eye Care
          • Antihistamines/Allergy Remedies (Systemic)
          • Child-Specific Allergy Remedies
          • Topical Allergy Remedies/Antihistamines
        • Child-Specific Consumer Health
          • Child-Specific Analgesics
            • Child-Specific Acetaminophen
            • Child-Specific Aspirin
            • Child-Specific Combination Products - Analgesics
            • Child-Specific Diclofenac
            • Child-Specific Dipyrone
            • Child-Specific Ibuprofen
            • Child-Specific Ketoprofen
            • Child-Specific Naproxen
          • Child-Specific Cough, Cold and Allergy Remedies
            • Child-Specific Allergy Remedies
            • Child-Specific Cough/Cold Remedies
          • Child-Specific Digestive Remedies
            • Child-Specific Diarrhoeal Remedies
            • Child-Specific Indigestion and Heartburn Remedies
            • Child-Specific Laxatives
            • Child-Specific Motion Sickness Remedies
          • Child-Specific Medicated Skin Care
          • Nappy (Diaper) Rash Treatments
          • Child-Specific Vitamins and Dietary Supplements

      Statistics Included

      Statistics Included

      For each category and subcategory you will receive the following data in Excel format:

      From Passport

      • Market Sizes
      • Company Shares
      • Brand Shares
      • Distribution
      • Analysis by Format
      • Analysis by Positioning
      • Analysis by Type
      • Herbal/Traditional vs Standard
      • Pricing

      Market size details:

      • Retail volume
      • Retail volume % growth
      • Retail volume per capita
      • Retail value retail selling price % growth
      • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
      • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
      • Retail value retail selling price real (constant 2008) prices % growth
      • Retail value retail selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
      • Retail value retail selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price % growth
      • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price real (constant 2008) prices % growth
      • Retail value manufacturer selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
      • Retail value retail selling price nominal (current) prices % growth
      • Retail value retail selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
      • Retail value retail selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price nominal (current) prices % growth
      • Retail value manufacturer selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
      • Retail value manufacturer selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY

      Methodology

      Methodology

      Global insight and local knowledge

      With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

      This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

      Industry specialists

      Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

      Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

      The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

      Country and regional analysts

      Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

      In-country research network

      To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

      Research Methodology

      Our research methods

      Each Euromonitor International industry report is based on a core set of research techniques:

      Desk research

      With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

      • National statistics offices governmental and official sources
      • National and international trade press
      • National and international trade associations
      • Industry study groups and other semi-official sources
      • Company financials and annual reports
      • Broker reports
      • Online databases
      • The financial, business and mainstream press

      Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

      Store checks

      Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

      • Place: We track products in all relevant channels, selective and mass, store and non-store
      • Product: What are innovations in products, pack sizes and formats?
      • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
      • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

      Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

      Trade survey

      Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

      Trade surveys allow us to:

      • Fill gaps in available published data per company
      • Generate a consensus view of the size, structure and strategic direction of the category
      • Access year-in-progress data where published sources are out of date
      • Evaluate the experts’ views on current trends and market developments

      In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

      Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

      Company analysis

      At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

      At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

      Forecasts

      Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

      Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

      Data validation

      All data is subjected to an exhaustive review process, at country, regional and global levels.

      The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

      Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

      Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

      Market analysis

      Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

      Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

      my pages

      Want to find out more about this report?

      RELATED

      Consumer Lifestyle

      Future Demographic

      Country Report